-
Cambrex Announces Strategic Agreement with Lilly to Support Biotech Collaborator Manufacturing
PR Newswire
December 05, 2024
Cambrex announced today that it has signed an agreement with Eli Lilly and Company (Lilly) to deliver accelerated access to clinical development capabilities for Lilly's biotech collaborators.
-
Lilly's Bebtelovimab Receives EUA to Treat COVID-19
contractpharma
February 14, 2022
bebtelovimab is an antibody that demonstrates neutralization against the Omicron variant.
-
Abbisko Therapeutics and Lilly partner to develop new molecules
Pharmaceutical-Technology
January 19, 2022
Abbisko is eligible to receive up to $258m in milestone payments from Lilly.
-
Abbisko Therapeutics Announces Worldwide Collaboration with Lilly to Discover and Develop Novel Molecules
prnasia
January 18, 2022
Collaboration Combines Abbisko Therapeutics' Proprietary Drug Discovery Platform with Lilly's Disease and Discovery Expertise.
Abbisko Therapeutics Is Eligible to Receive Research, Development and Commercial Milestone Payments.
-
Lilly Acquires Rights to Entos Pharmaceuticals' Fusogenix Tech
contractpharma
January 06, 2022
Novel delivery platform technology has the potential to solve a key delivery challenge for many nucleic acid therapeutic modalities.
-
Lilly and Foghorn enter partnership to develop new cancer medicines
Pharmaceutical-Technology
December 15, 2021
Eli Lilly and Company’s research and development group Loxo Oncology at Lilly and Foghorn Therapeutics have entered a strategic partnership to develop new cancer therapies.
-
Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control® Platform
AmericanPharmaceuticalReview
December 14, 2021
Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company and Foghorn Therapeutics Inc. announced a strategic collaboration to create novel oncology medicines by applying Foghorn's proprietary Gene Traffic Control® platform...
-
Lilly and Regor Therapeutics Collaborate to Discover and Develop Novel Therapies for Metabolic Disorders
AmericanPharmaceuticalReview
December 13, 2021
Eli Lilly and Company and Regor Therapeutics Group have entered into a multi-year research collaboration and licensing agreement to discover, develop and commercialize novel therapies for metabolic disorders.
-
Lilly and Regor sign deal to develop treatments for metabolic disorders
Pharmaceutical-Technology
December 13, 2021
Eli Lilly and Company and Regor Therapeutics Group have signed an agreement to discover, develop and market new treatments for metabolic disorders.
-
FDA grants EUA to Lilly’s Covid-19 antibody therapy for paediatric use
Pharmaceutical-Technology
December 07, 2021
The EUA has been granted based on safety and efficacy data from the BLAZE-1 trial in paediatric and infant Covid-19 patients.
ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight June 2024: Globalization on the Go
